Product Benefits
| Core Benefit | Mechanism |
| Dual Mechanism of Action | Combines two complementary drugs to target different pathways of high blood sugar: Linagliptin enhances incretin hormones, and Metformin reduces liver glucose production. |
| Enhanced Glycemic Control | This synergistic action provides more robust blood sugar lowering compared to either agent used alone, leading to significant reduction in $\text{HbA}_{1\text{c}}$ levels. |
| Convenient Once-Daily Dosing | The Extended Release ($\text{ER}$) formulation of Metformin allows the medication to be taken only once daily with a meal, greatly improving patient adherence and simplicity of the treatment regimen. |
| Low Hypoglycemia Risk | Linagliptin's mechanism is glucose-dependent (it only works when blood sugar is high), and Metformin inherently carries a low risk of causing hypoglycemia (low blood sugar) when used as monotherapy. |
⚠️ Important Safety Note: Diabetes Combination Tablet
Prescription Required: This drug is only available by prescription and requires medical supervision. Do not crush, chew, or split the extended-release tablet.
Lactic Acidosis: Metformin carries a Black Box Warning for the rare but serious risk of lactic acidosis, especially in patients with severe kidney impairment. Kidney function must be monitored regularly.
Pancreatitis: Linagliptin has been associated with reports of acute pancreatitis. Seek medical attention immediately if you experience severe abdominal pain.
Offer Products
Face Care
Hair Care
stationery & office
Tea & Coffee
Baby Wipes
Cream
Baby Essentials
Fragrances
Lip Care
Body Care
Air Freshener
Customer questions & answers
Customer reviews
0 out of 5